[Response characteristics of tislelizumab combined with chemotherapy in first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer].
Lu S, Yu XM, Hu YP, Ma ZY, Li XY, Li WD, Liu YP, Wang D, Wang XW, Wang ZH, Wu JX, Zhong DS, Li GF, He WY, Bao YY, Yuan Y, Fan JH.
Lu S, et al. Among authors: yu xm.
Zhonghua Zhong Liu Za Zhi. 2023 Apr 23;45(4):358-367. doi: 10.3760/cma.j.cn112152-20220928-00662.
Zhonghua Zhong Liu Za Zhi. 2023.
PMID: 37078218
Clinical Trial.
Chinese.